Last reviewed · How we verify
Apatinib Mesylate, Gefitinib
Apatinib Mesylate, Gefitinib is a Tyrosine kinase inhibitor Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 1 development for Non-small cell lung cancer.
Tyrosine kinase inhibitor of VEGFR-2 and c-KIT
Tyrosine kinase inhibitor of VEGFR-2 and c-KIT Used for Non-small cell lung cancer.
At a glance
| Generic name | Apatinib Mesylate, Gefitinib |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Tyrosine kinase inhibitor |
| Target | VEGFR-2 and c-KIT |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Apatinib mesylate is a potent inhibitor of VEGFR-2 and c-KIT tyrosine kinases, which are involved in tumor angiogenesis and cell proliferation.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients (PHASE1)
- Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance (PHASE2)
- Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer (PHASE2)
- Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC (PHASE2)
- Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer (PHASE1)
- A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apatinib Mesylate, Gefitinib CI brief — competitive landscape report
- Apatinib Mesylate, Gefitinib updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about Apatinib Mesylate, Gefitinib
What is Apatinib Mesylate, Gefitinib?
How does Apatinib Mesylate, Gefitinib work?
What is Apatinib Mesylate, Gefitinib used for?
Who makes Apatinib Mesylate, Gefitinib?
What drug class is Apatinib Mesylate, Gefitinib in?
What development phase is Apatinib Mesylate, Gefitinib in?
What are the side effects of Apatinib Mesylate, Gefitinib?
What does Apatinib Mesylate, Gefitinib target?
Related
- Drug class: All Tyrosine kinase inhibitor drugs
- Target: All drugs targeting VEGFR-2 and c-KIT
- Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Compare: Apatinib Mesylate, Gefitinib vs similar drugs
- Pricing: Apatinib Mesylate, Gefitinib cost, discount & access